...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Immunology >Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease
【24h】

Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease

机译：靶向髓样来源的细胞：非酒精性和酒精性肝病治疗的新领域

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-alcoholic fatty liver disease (NAFLD) and Alcoholic Liver Disease (ALD) are major causes of liver-related morbidity and mortality and constitute important causes of liver transplantation. The spectrum of the liver disease is wide and includes isolated steatosis, steatohepatitis, and cirrhosis. The treatment of NAFLD and ALD remains, however, an unmet need, and therefore it is a public health priority to develop effective treatments for these diseases. Alcoholic and non-alcoholic liver disease share common complex pathogenetic pathways that involve different organs and systems beyond the liver, including the gut, the adipose tissue, and the immune system, which cross-talk to generate damage. Myeloid-derived cells have been widely studied in the setting of NAFLD and ALD and are implicated at different levels in the onset and progression of this disease. Among these cells, monocytes and macrophages have been found to be involved in the induction of inflammation and in the progression to fibrosis, both in animal models and clinical studies and they have become interesting potential targets for the treatment of both NAFLD and ALD. The different mechanisms by which these cells can be targeted include modulation of Kupffer cell activation, monocyte recruitment in the liver and macrophage polarization and differentiation. Evidence from preclinical studies and clinical trials (some of them already in phase II and III) have shown encouraging results in ameliorating steatohepatitis, fibrosis, and the metabolic profile, individuating promising candidates for the pharmacological treatment of these diseases. The currently available results of myeloid-derived cells targeted treatments in NAFLD and ALD are covered in this review.
机译：非酒精性脂肪肝疾病（NAFLD）和酒精性肝病（ALD）是肝脏相关发病率和死亡率的主要原因，并且是肝脏移植的重要原因。肝病的范围很广，包括单纯性脂肪变性，脂肪性肝炎和肝硬化。然而，NAFLD和ALD的治疗仍未得到满足，因此，开发针对这些疾病的有效治疗是公共卫生的当务之急。酒精性和非酒精性肝病具有共同的复杂的致病性途径，涉及肝脏以外的不同器官和系统，包括肠道，脂肪组织和免疫系统，它们相互串扰以产生损害。髓样来源的细胞已经在NAFLD和ALD的背景下得到了广泛的研究，并以不同的水平牵涉这种疾病的发作和发展。在动物模型和临床研究中，已发现在这些细胞中，单核细胞和巨噬细胞与炎症的诱导和向纤维化的发展有关，它们已成为治疗NAFLD和ALD的有趣潜在靶标。这些细胞可被靶向的不同机制包括调节Kupffer细胞活化，肝脏中单核细胞募集以及巨噬细胞极化和分化。临床前研究和临床试验（其中一些已经在II和III期）的证据显示，在改善脂肪性肝炎，纤维化和代谢状况方面，令人鼓舞的结果令人鼓舞，这些药物有望用于这些疾病的药理学治疗。本综述涵盖了NAFLD和ALD中髓样来源的细胞靶向治疗的当前可用结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号